How many drugs treat Hyperphosphatemia?

Drug Landscape tracks 4 marketed treatments for Hyperphosphatemia (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/hyperphosphatemia.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Hyperphosphatemia — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hyperphosphatemia (disease) competitive landscape: 4 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

4 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Hyperphosphatemia, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	First approval
Auryxia	FERRIC CITRATE	Keryx Biopharms	ferric citrate	2014-01-01
Ferrlecit	sucroferric oxyhydroxide	Vifor Fresenius	Phosphate Binder [EPC]	2013-01-01
Colestimide	colestilan	Tanabe Pharma Corporation	colestilan
Velphoro	Velphoro	RWTH Aachen University

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Keryx Biopharms · 1 drug in Hyperphosphatemia
RWTH Aachen University · 1 drug in Hyperphosphatemia
Tanabe Pharma Corporation · 1 drug in Hyperphosphatemia
Vifor Fresenius · 1 drug in Hyperphosphatemia

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Hyperphosphatemia:

Cite this brief

Drug Landscape (2026). Hyperphosphatemia — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/hyperphosphatemia. Accessed 2026-06-10.

Hyperphosphatemia full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing